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A symposium on "Polycyclic Aromatic
Hydrocarbons (PAHs) in Carcinogenesis" was
presented at the third International Congress
ofPathophysiology held in Lathi, Finland, 28
June-3 July 1998. The congress was also
sponsored by the International Union of
Biological Sciences and the International
Society ofFree Radical Research. Institutional
support for the symposium included the
Electric Power Research Institute, National
Center for Toxicological Research, and
EPA/National Health and Environmental
Effects Research Laboratory and the Office of
Solid Waste and Emergency Response. The
symposium focused on the sources, carcino-
genicity, genotoxicity, and risk assessment of
individual and mixtures of PAHs that are
found in solid wastes, Superfund sites, and
other hazardous waste sites. Based on the
occurrence ofPAHs at numerous Superfund
sites and the significant data gaps on the toxic
potential of certain PAHs, the information
developed during this symposium would be
of value in assessing health risks of these
chemicals at Superfund and other hazardous
waste sites.
Seven lectures were presented at the sym-
posium. The first presentation dealt with
sources of PAHs and those that were most
commonly found on the National Priority
List (NPL) (1). The second presentation dis-
cussed the mechanisms of activation of
PAHs and N-heterocyclic aromatics (NHAs)
in target tissues. The next three lectures dealt
with synthetic and natural mixtures. The
first of these reported on the relationship
between synthetic mixtures and lung cancer
in the mouse. The second lecture dealt with
the tumorigenicity in mice fed coal tar or
benzo[a]pyrene (B[a]P). The last of these
lectures dealt with genotoxicity studies with
reconstituted and field-derived PAH mix-
tures. The final two lectures were concerned
with risk assessment of PAHs; the first was
on the risk ofcoal tar mixtures and the sec-
ond on the risk ofenvironmental samples of
PAHs.
Most U.S. hazardous waste sites listed on
the NPL (Superfund or NPL sites) are conta-
minated with complex mixtures ofchemicals
that have migrated over time into several
environmental media. To date, 1,410 sites
have been listed or areproposed forlisting on
the NPL. PAHs have been identified as cont-
aminants ofconcern at 352 ofthese sites and
have been found in soil, groundwater, and
sediment. Routine sampling ofmedia for 16
PAHs containing from two to six aromatic
rings occurs at sites with suspected PAH
contamination. PAHs are commonly found
at manufactured gas plant sites, wood-treat-
ing facilities, municipal and industrial land-
fills, manufacturing and chemical plants,
and military and other federal facilities.
B[a]P is the most commonlyidentified PAH
at manufactured gas plant (MGP) sites.
B[a]P is the most frequendy identified PAH
in all media (247 sites), in soil (198 sites),
and in sediment (54 sites). Naphthalene is
the most frequently occurring PAH in
groundwater (125 sites).
The sources ofPAHs were followed by
a discussion of the formation of DNA
adducts and oncogene-activating mutations
by environmental pollutants (in particular,
NHAs) that are found in complex mix-
tures. Complex mixtures that are produced
from the combustion of organic materials
have been associated with increased cancer
mortality. These mixtures, such as tobacco
condensate, automobile exhaust, and efflu-
ents from coal combustion contain homo-
cyclic and heterocyclic PAHs. To better
assess the contribution ofNHAs to the car-
cinogenic potency ofcomplex mixtures and
to develop biomarkers of the carcinogenic
process, studies were undertaken to assess
the metabolic activation of NHAs. In par-
ticular, 7H-dibenzo[c,glcarbazole (DBC)
and dibenz[a,jlacridine (DBA) were select-
ed for study as model compounds based on
animal testing. DBC and DBA were car-
cinogenic in more than one tissue. Both
compounds are symmetric around their C2
axis; the only difference is that the middle
ring for DBC has a pyrrole ring, whereas
DBAhas apyridine ring.
DBC has both local and systemic effects
in the mouse; it is a potent skin and liver
carcinogen following topical application and
a lung carcinogen following intraperitoneal
injection. DBC-DNA adducts are formed
through phenols or directly through radical
cations. In addition, the DBC-DNA
adduct pattern consisting of seven adducts
based on the 32P-postlabeling technique is
target-organ specific forlung, liver and skin.
As a result of DBC exposure, mutations in
H-rasoncogene in skin and liver tumors are
found exclusively in the second base of
codon 61 byA to T transversions. Similarly,
the majority of mutations in K-ras in lung
tumors in the third base ofcodon 61 are A
to T transversions, whereas mutations in the
second base are A to T transversions with a
fewA to G transitions.
In contrast, DBA is a moderate mouse
skin carcinogen following topical applica-
tion and a lung carcinogen following subcu-
taneous injection. DBA is metabolized to
trans-dihydrodiols. DBA-DNA adducts are
formed in skin through an active metabo-
lite, the dihydrodiolepoxide, which binds to
deoxyadenosine and deoxyguanosine
residues. Mutations in the H-ras gene in
skin tumors as a result ofDBA exposure are
found in codons 12, 13, and 61. These
mutations involve G to T andA to T trans-
versions in the second base and are consis-
tentwith the DNAbinding ofDBA.
These results indicate that although the
two compounds are structurally similar, dif-
fering by only one carbon in the middle
ring, there are major differences in their
metabolic activation, induding metabolism,
DNA binding, mutation, and carcinogene-
sis. The biological differences for DBC and
DBA are reflected in target-organ-specific
proximate and mutagenic metabolites,
DNA adduct patterns, and the resulting
mutational spectra.
It was indicated that although some
environmental hazards involve significant
exposure to only a single compound, most
instances of environmental contamination
involve concurrent or sequential exposure to
a mixture of compounds. Multichemical
exposures are ubiquitous in air, water, and
waste sites; therefore, these exposures are an
important component of risk assessments.
Although the individual components in a
mixture may each induce toxic effects, they
may also interact with the host organism in
a manner that increases or decreases the
observed toxic effects of each component.
The default assumption that the EPA uses
for assessing the risk for chemical mixture
exposure is to assume that there are no inter-
actions and that the toxic response observed
is the additive sum ofthe toxic responses of
each component.
This default assumption in cancer risk
assessment was tested using a mixture offive
environmental and carcinogenic PAHs:
B[a]P, benzo[b]fluoranthene, dibenz[a,h]-
anthracene, 5-methylchrysene, and cyclopen-
ta[c,apyrene. Using lung tumors in strain
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A/J mice as a measure oftumorigenic activi-
ty and response surface modeling as the ana-
lytic method, we found that less than addi-
tive and greater than additive interactions
were dose related. Response surface analysis
produced statistically significant values for
10 interaction parameters. All ofthe binary
interaction functions were antagonistic and
were dominated by dibenz[a,h]anthracene.
The response surface model dosely predict-
ed the observed lung tumorigenic responses
of all the quintary mixtures as well as the
dose-response curves of each individual
PAH component. Although there were sig-
nificant interactions, the extent of these
interactions was limited (approximately
twofold) and the EPA default assumption
within the bounds ofthe studywas support-
ed and, therefore, these interactions proba-
bly will not have a major influence in the
risk assessment.
In lifetime feeding studies with female
B6C3F1 mice, environmental coal tars were
tumorigenic in the small intestine, liver,
lung, and forestomach. Coal tars also
induced sarcomas ofskin and histiosarcomas
and hemangiosarcomas in various organs. In
contrast, B[a]P induced tumors in the
tongue, larynx, esophagus, and forestomach.
Because the PAHs in general and B[a]P in
particular are thought to play a role in car-
cinogenesis by coal tars, studies were con-
ducted to compare the effects ofcoal tars to
a single component (B[a]P) within the tars.
Using the 32P-postlabeling assay, DNA
adduct levels were measured in the lung,
liver, and forestomach of B6C3F1 mice fed
coal tar or B[a]P for 4 weeks. All three tissue
sites demonstrated dose-dependent increases
in DNA adduct levels, indicating that both
B[a]P and coal tar PAHs were transported
to the organ sites, even though no lung or
liver tumors were found in the B[a]P-treated
mice. The nature ofthe coal tar adducts in
lung was investigated further by extracting
the radioactive area of the thin-layer chro-
matography (TLC) plate corresponding to
100-(deoxyguanosin-N2-yl)-7p,8a,9a-tri-
hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene
(N2-dG-BPDE), the major adduct formed
by B[a]P, and eluting through a column
containing a monoclonal antibody to A2-
dG-BPDE. Adducts from lung DNA from
B[a]P-treated mice were bound to the col-
umn, extracted, and produced a single
HPLC peak. In contrast, in coal-tar-treated
mice, approximately halfofthe radioactivity
in the N2-dG-BPDE area on the TLC plates
did not bind to the antibody. Extraction of
the remainingradioactivity from the column
produced a number of HPLC peaks, sug-
gesting multiple adducts. Because the anti-
body has specificity for other PAH adducts,
the results indicate that additional adducts
were formed in coal-tar-treated mice and
may participate in processes leading to
tumor formation.
B[a]P- and coal-tar-induced mutagene-
sis in the K-ras oncogene in forestomach
tumors were also investigated. Both coal tar
and B[a]P induced mutations in guanine at
positions 1 and 2 in codons 12 and 13.
Mutations at guanine were also found in
lung tumors, but not in tumors of the
small intestine in coal-tar-treated mice.
Therefore, K-ras mutations may play a role
in lung and forestomach tumors, but are
not involved in small intestine tumors.
B[a]P dominates the cancer risk esti-
mate when its concentration is >6,300 ppm
in the coal tar mixture. In this case, the
most sensitive tissue site is the forestomach.
If the B[a]P concentration is <6,300 ppm,
the more likely case, then lung tumors pro-
vide the largest estimated upper limit of
cancer risk in humans exposed to coal tars.
A multistage model was fit to the data and
gave the relationship as follows: 1) risk
<2.55 x percentage ofcoal tar in diet, or 2)
risk <2.55 x 10-4 ppm coal tar in diet.
Coal tars aged in the soils may not be
completely bioavailable to organisms when
ingested or absorbed through skin. The
bioavailable dose under these exposure con-
ditions is less than would be calculated from
exhaustive chemical extraction and charac-
terization ofPAH-contaminated media.
B[a]P alone did not account for all
tumors induced by coal tars. Tumorigenesis
by coal tars appears to reflect the contribu-
tion ofchemicals other than B[a]P or reflect
the modification of B[a]P activity by other
chemicals in the coal tar. The data suggest
that, for risk estimation, regulatory
approaches based solely on the B[a]P con-
tent ofcomplex mixtures of PAHs, such as
coal tars, should be reevaluated. B[a]P does
not appear to be responsible for the forma-
tion of tumors in the most sensitive site,
lung tumors, when the concentration of
B[a]P is <6,300 ppm in the coal tarmixture.
PAHs are major contaminants of oily
and MGP sites. A study was undertaken to
investigate the in vivo carcinogenicity and in
vitro genotoxicity of crude MGP-derived
PAHs, B[a]P, and a reconstituted mixture of
MGP-PAH hydrocarbons. Carcinogenicity
studies in juvenile male B6C3F1 mice
demonstrated that the hepatocarcinogenicity
of MGP residues is primarily due to com-
pounds other than the hydrocarbons. This
was also confirmed in mutagenicity and frac-
tionation assays, which suggest that alkyl
PAHs may be important components of
thesemixtures.
The risk assessments of PAH at the
EPA are carried out according to the
Guidelinesfor the Health Risk Assessment of
Chemical Mixtures (2) and the Guidelines
for Carcinogen RiskAssessment(2). Proposed
revisions to the cancer guidelines depart
from the former system ofalphanumeric
weight-of-evidence categories in favor of a
narrative classification statement. There is
emphasis on the use of data other than
tumor incidence in making judgments
about the relevance of cancer observations
(in animals or from specific exposure sce-
narios) to human risk assessment.
Assessment of the carcinogenicity of a
material under the revised guidelines is
heavily dependent on a consideration of
the mode of action by which it causes the
carcinogenic effects. Mode of action
informs both the hazard identification and
dose-response processes. B[a]P mode of
action can be characterized in this manner:
1) It is metabolized to reactive intermedi-
ates (including but not limited to diol-
epoxides) in various tissues ofthe body; 2)
these intermediates bind covalently to
DNA or cause damage in other ways; 3)
covalent binding to DNA can result in
mutations in critical genes and thus initiate
the carcinogenic process; 4) B[a]P is likely
to serve as its own promoter; and 5) B[a]P
may affect other stages of the carcinogenic
process such as inducing metabolism or
decreasing immune surveillance.
A revised hazard identification for B[a]P
considers the following: 1) B[a]P produces
tumors in every animal model in which it
has been applied; 2) B[a]P produces tumors
by all routes that have been tested; 3) B[a]P
produces tumors at multiple sites, including
sites distant from the point ofexposure; and
4) some B[a]P-containing mixtures are
known human carcinogens and many more
are known animal carcinogens.
Revised hazard characterizations for B[a]P
(and perhaps for other individual PAHs and
for mixtures containing PAHs) indicate that
these materials should be treated as ifthey are
known human carcinogens. Furthermore,
B[a]P (and perhaps others) should be consid-
ered carcinogenic byall routes. Ahazard char-
acterization of B[a]P should consider that
B[a]P exposure to humans is primarily
through inhalation, ingestion in food, and
throughdermal contact.
In summary, to determine appropriate
clean-up actions for sites, risks must be eval-
uated from exposures to all contaminants of
concern in all relevant media. In assessing
the cancer risks from complex chemical mix-
tures found at Superfund sites, the EPA's
hazardous waste program assumes that the
risks due to individual chemicals are addi-
tive. In evaluating cancer risks from PAHs,
the waste program currently analyzes the
cancer risks of B[a]P and six other carcino-
genic PARs, using B[a]P as the reference
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compound. Potential carcinogenic risks of
other PAHs are generally not considered.
Recent results oforal carcinogenicity studies
of B[a]P in female mice and two separate
mixtures ofMGP residues indicate that new
approaches to evaluating the cancer risks of
complex PAH mixtures should be consid-
ered. Additional research is also needed,
including toxicity/carcinogenicity studies of
individual PAHs and PAH mixtures,
bioavailability studies of individual PAHs
and PAH mixtures in environmental media,
and toxicity studies ofenvironmental degra-
dation products ofPAHs.
Furthermore, carcinogenicity is the signa-
ture end point, but data are limited for other
health effects. Studies should be conducted to
allow assessment of immunotoxicity, devel-
opmental toxicity, and reproductive effects of
PAHs. Quantitative assessment for B[a]P
should use a low-dose linear approach based
on the strong evidence for a mutagenic mode
of action including irreversible changes.
Appropriate physiologically based pharmaco-
kinetic models should be applied to arrive at
target doses. It should be possible to extend
the observed range ofthe B[a]P dose response
using nontumor data such as specific DNA
adducts ormutation frequencies.
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